Skip to main content

Advertisement

SpringerLink
Log in

Circulating fibroblast growth factor 21 in patients with liver cirrhosis

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Fibroblast growth factor 21 (FGF21) is an adipokine and hepatokine, and its hepatic expression is induced in the injured liver. Adiponectin, whose systemic levels are positively correlated with measures of hepatic injury in patients with liver cirrhosis, is a downstream effector of FGF21. The aim of the present study was to identify possible associations of serum FGF21 with measures of liver function in patients with liver cirrhosis. FGF21 was determined by ELISA in serum of 42 patients. FGF21 was not linked to disease severity assessed by the Child–Pugh and MELD score. Levels were not changed in those patients with varices and/or ascites. Systemic FGF21 did not correlate with markers of liver and kidney function, inflammatory proteins or adipokines like adiponectin. Levels in hepatic and portal vein of 37 patients were also measured, but there was no transhepatic FGF21 gradient. Three months after insertion of a transjugular intrahepatic shunt hepatic venous pressure gradient was markedly improved, while FGF21 in serum of these 13 patients was not changed. The present study shows that hepatic release and systemic FGF21 are not linked to measures of liver function in patients with liver cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31. doi:10.1016/j.jhep.2005.10.013.

    Article  PubMed  Google Scholar 

  2. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767–77. doi:10.1056/NEJMra1504367.

    Article  CAS  PubMed  Google Scholar 

  3. Kawaratani H, Fukui H, Yoshiji H. Treatment for cirrhotic ascites. Hepatol Res. 2016;. doi:10.1111/hepr.12769.

    Google Scholar 

  4. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology. 1994;19:616–27.

    Article  CAS  PubMed  Google Scholar 

  5. Carr RM, Correnti J. Insulin resistance in clinical and experimental alcoholic liver disease. Ann N Y Acad Sci. 2015;1353:1–20. doi:10.1111/nyas.12787.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Degre D, Gustot T, Gerkens A, et al. Insulin resistance is associated with esophageal varices in alcoholic liver disease patients. Eur J Gastroenterol Hepatol. 2016;28:792–6. doi:10.1097/MEG.0000000000000627.

    Article  CAS  PubMed  Google Scholar 

  7. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17:2801–11. doi:10.3748/wjg.v17.i23.2801.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55–63. doi:10.1038/nm.2277.

    Article  CAS  PubMed  Google Scholar 

  9. Eslam M, Ampuero J, Jover M, et al. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol. 2013;12:588–98.

    PubMed  Google Scholar 

  10. Kakizaki S, Sohara N, Yamazaki Y, et al. Elevated plasma resistin concentrations in patients with liver cirrhosis. J Gastroenterol Hepatol. 2008;23:73–7. doi:10.1111/j.1440-1746.2006.04757.x.

    Article  CAS  PubMed  Google Scholar 

  11. Kalafateli M, Triantos C, Tsochatzis E, et al. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World J Gastroenterol. 2015;21:3020–9. doi:10.3748/wjg.v21.i10.3020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med. 2005;258:274–80. doi:10.1111/j.1365-2796.2005.01543.x.

    Article  CAS  PubMed  Google Scholar 

  13. Kasztelan-Szczerbinska B, Surdacka A, Slomka M, et al. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. Mediat Inflamm. 2013;2013:148526. doi:10.1155/2013/148526.

    Article  Google Scholar 

  14. Halberg N, Schraw TD, Wang ZV, et al. Systemic fate of the adipocyte-derived factor adiponectin. Diabetes. 2009;58:1961–70. doi:10.2337/db08-1750.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wiest R, Moleda L, Farkas S, et al. Splanchnic concentrations and postprandial release of visceral adipokines. Metabolism. 2010;59:664–70. doi:10.1016/j.metabol.2009.09.011.

    Article  CAS  PubMed  Google Scholar 

  16. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004;287:E82–9. doi:10.1152/ajpendo.00494.2003.

    Article  CAS  PubMed  Google Scholar 

  17. Dasarathy J, Alkhouri N, Dasarathy S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liv Int. 2011;31:1250–8. doi:10.1111/j.1478-3231.2011.02498.x.

    Article  Google Scholar 

  18. Holland-Fischer P, Nielsen MF, Vilstrup H, et al. Insulin sensitivity and body composition in cirrhosis: changes after TIPS. Am J Physiol Gastrointest Liv Physiol. 2010;299:G486–93. doi:10.1152/ajpgi.00375.2009.

    Article  CAS  Google Scholar 

  19. Thomsen KL, Sandahl TD, Holland-Fischer P, et al. Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism. Clin Nutr. 2012;31:940–5. doi:10.1016/j.clnu.2012.04.001.

    Article  CAS  PubMed  Google Scholar 

  20. Muise ES, Azzolina B, Kuo DW, et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol. 2008;74:403–12. doi:10.1124/mol.108.044826.

    Article  CAS  PubMed  Google Scholar 

  21. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203–6.

    Article  CAS  PubMed  Google Scholar 

  22. Xu J, Lloyd DJ, Hale C, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250–9. doi:10.2337/db08-0392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Quesada-Lopez T, Cereijo R, Turatsinze JV, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun. 2016;7:13479. doi:10.1038/ncomms13479.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17:779–89. doi:10.1016/j.cmet.2013.04.005.

    Article  CAS  PubMed  Google Scholar 

  25. Cheng X, Vispute SG, Liu J, et al. Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR). Toxicol Appl Pharmacol. 2014;278:65–71. doi:10.1016/j.taap.2014.04.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yang C, Lu W, Lin T, et al. Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13:67. doi:10.1186/1471-230X-13-67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014;147(1073–83):e6. doi:10.1053/j.gastro.2014.07.044.

    Google Scholar 

  28. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000. doi:10.1136/gut.2009.193227.

    Article  PubMed  Google Scholar 

  29. Bauer S, Eisinger K, Wiest R, et al. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. Regul Pept. 2012;179:10–4. doi:10.1016/j.regpep.2012.08.007.

    Article  CAS  PubMed  Google Scholar 

  30. Eisinger K, Krautbauer S, Wiest R, et al. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013;43:926–32. doi:10.1111/eci.12122.

    Article  CAS  PubMed  Google Scholar 

  31. Eisinger K, Krautbauer S, Wiest R, Weiss TS, Buechler C. Reduced serum chemerin in patients with more severe liver cirrhosis. Exp Mol Pathol. 2015;98:208–13. doi:10.1016/j.yexmp.2015.01.010.

    Article  CAS  PubMed  Google Scholar 

  32. Wanninger J, Weigert J, Wiest R, et al. Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Cytokine. 2011;55:435–40. doi:10.1016/j.cyto.2011.06.001.

    Article  CAS  PubMed  Google Scholar 

  33. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010;72:342–8. doi:10.1111/j.1365-2265.2009.03664.x.

    Article  CAS  Google Scholar 

  34. Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract. 2014;104:53–62. doi:10.1016/j.diabres.2014.01.003.

    Article  CAS  PubMed  Google Scholar 

  35. Goral V, Atalay R, Kucukoner M. Insulin resistance in liver cirrhosis. Hepatogastroenterology. 2010;57:309–15.

    PubMed  Google Scholar 

  36. Müller-Wieland D, Petermann A, Nauck M, Heinemann L, Kerner W, Müller UA, Landgraf R. Definition, klassifikation und diagnostik des diabetes mellitus. Diabetologie. 2016;11(Suppl 2):S78–81. doi:10.1055/s-0042-115159 (© Georg Thieme Verlag KG Stuttgart, New York, 2016).

    Google Scholar 

  37. Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. Dig Dis. 2016;34:410–22. doi:10.1159/000444556.

    Article  PubMed  Google Scholar 

  38. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab J. 2013;37:404–14. doi:10.4093/dmj.2013.37.6.404.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Vashist SK, Venkatesh AG, Marion Schneider E, et al. Bioanalytical advances in assays for C-reactive protein. Biotechnol Adv. 2015;34:272–90. doi:10.1016/j.biotechadv.2015.12.010.

    Article  PubMed  Google Scholar 

  40. Ucar F, Sezer S, Ginis Z, et al. APRI, the FIB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25:1076–81. doi:10.1097/MEG.0b013e32835fd699.

    Article  CAS  PubMed  Google Scholar 

  41. Kukla M, Berdowska A, Stygar D, et al. Serum FGF21 and RBP4 levels in patients with chronic hepatitis C. Scand J Gastroenterol. 2012;47:1037–47. doi:10.3109/00365521.2012.694901.

    Article  CAS  PubMed  Google Scholar 

  42. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53:934–40. doi:10.1016/j.jhep.2010.05.018.

    Article  CAS  PubMed  Google Scholar 

  43. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542–6. doi:10.2337/dc09-0684.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2014;80:57–64. doi:10.1111/cen.12134.

    Article  CAS  Google Scholar 

  45. Salman TA, Allam N, Azab GI, et al. Study of adiponectin in chronic liver disease and cholestasis. Hepatol Int. 2010;4:767–74. doi:10.1007/s12072-010-9216-0.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hindricks J, Ebert T, Bachmann A, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf). 2014;80:918–24. doi:10.1111/cen.12380.

    Article  CAS  Google Scholar 

  47. Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE. 2011;6:e18398. doi:10.1371/journal.pone.0018398.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Matuszek B, Lenart-Lipinska M, Duma D, Solski J, Nowakowski A. Evaluation of concentrations of FGF-21—a new adipocytokine in type 2 diabetes. Endokrynol Pol. 2010;61:50–4.

    CAS  PubMed  Google Scholar 

  49. Li X, Fan X, Ren F, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011;93:10–6. doi:10.1016/j.diabres.2011.02.034.

    Article  CAS  PubMed  Google Scholar 

  50. Pohl R, Haberl EM, Rein-Fischboeck L, et al. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. Eur J Clin Invest. 2017;47:7–18. doi:10.1111/eci.12695.

    Article  CAS  PubMed  Google Scholar 

  51. Berti L, Hartwig S, Irmler M, et al. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem. 2016;122:281–8. doi:10.1080/13813455.2016.1212898.

    Article  CAS  PubMed  Google Scholar 

  52. Imai K, Takai K, Hanai T, et al. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int J Mol Sci. 2014;15:11294–306. doi:10.3390/ijms150711294.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Sun B, Yang G, Yang M, et al. Long-term high-fat diet links the regulation of the insulin-sensitizing fibroblast growth factor-21 and visfatin. Cytokine. 2012;59:131–7. doi:10.1016/j.cyto.2012.03.030.

    Article  CAS  PubMed  Google Scholar 

  54. Gudowska M, Gruszewska E, Cylwik B, et al. Galectin-3 concentration in liver diseases. Ann Clin Lab Sci. 2015;45:669–73.

    CAS  PubMed  Google Scholar 

  55. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol. 2006;101:1244–52. doi:10.1111/j.1572-0241.2006.00543.x.

    Article  CAS  PubMed  Google Scholar 

  56. Benten D, Schulze zur Wiesch J, Sydow K, et al. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). BMC Gastroenterol. 2011;11:107. doi:10.1186/1471-230X-11-107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was in part supported by the “Stiftung für Pathobiochemie und Molekulare Diagnostik.”

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany

    Sabrina Krautbauer, Lisa Rein-Fischboeck, Elisabeth M Haberl, Rebekka Pohl & Christa Buechler

  2. Department of Visceral Surgery and Medicine, University Inselspital, Bern, Switzerland

    Reiner Wiest

Authors
  1. Sabrina Krautbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Rein-Fischboeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabeth M Haberl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rebekka Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reiner Wiest
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christa Buechler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christa Buechler.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

The study complies with the Declaration of Helsinki. All patients gave written informed consent, and the study was approved by the Ethical Committee of the University Hospital of Regensburg.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krautbauer, S., Rein-Fischboeck, L., Haberl, E.M. et al. Circulating fibroblast growth factor 21 in patients with liver cirrhosis. Clin Exp Med 18, 63–69 (2018). https://doi.org/10.1007/s10238-017-0468-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-017-0468-z

Keywords

Search

Navigation